Merck & Company Inc (MRK)vsTG Therapeutics Inc (TGTX)
MRK
Merck & Company Inc
$119.60
+0.84%
HEALTHCARE · Cap: $283.78B
TGTX
TG Therapeutics Inc
$53.94
-0.99%
HEALTHCARE · Cap: $7.58B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 9291% more annual revenue ($65.77B vs $700.35M). TGTX leads profitability with a 65.9% profit margin vs 13.6%. TGTX appears more attractively valued with a PEG of 1.61. TGTX earns a higher WallStSmart Score of 70/100 (B-).
MRK
Hold50
out of 100
Grade: D+
TGTX
Strong Buy70
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-40.6%
Fair Value
$80.96
Current Price
$119.60
$38.64 premium
Intrinsic value data unavailable for TGTX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 38.6%
Generating 2.9B in free cash flow
Every $100 of equity generates 79 in profit
Keeps 66 of every $100 in revenue as profit
Revenue surging 69.6% year-over-year
Earnings expanding 300.0% YoY
Attractively priced relative to earnings
Areas to Watch
Premium valuation, high expectations priced in
4.9% revenue growth
Elevated debt levels
Weak financial health signals
Expensive relative to growth rate
Trading at 13.1x book value
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Operating Margin, Free Cash Flow.
Bull Case : TGTX
The strongest argument for TGTX centers on Return on Equity, Profit Margin, Revenue Growth. Profitability is solid with margins at 65.9% and operating margin at 17.0%. Revenue growth of 69.6% demonstrates continued momentum.
Bear Case : MRK
The primary concerns for MRK are P/E Ratio, Revenue Growth, Debt/Equity.
Bear Case : TGTX
The primary concerns for TGTX are PEG Ratio, Price/Book, Debt/Equity.
Key Dynamics to Monitor
MRK profiles as a value stock while TGTX is a growth play — different risk/reward profiles.
TGTX carries more volatility with a beta of 1.68 — expect wider price swings.
TGTX is growing revenue faster at 69.6% — sustainability is the question.
MRK generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
TGTX scores higher overall (70/100 vs 50/100), backed by strong 65.9% margins and 69.6% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →TG Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?